ライフサイエンスコーパス: societal cost

1 (AUDs) affect people at great individual and societal cost.

2 n with significant morbidity, mortality, and societal cost.

3 others' rights and represent a considerable societal cost.

4 mmon disorder, has substantial morbidity and societal cost.

5 health-care-payer cost and 87% of the total societal costs.

6 rect healthcare expenses as well as indirect societal costs.

7 nosis and treatment for reducing MVA-related societal costs.

8 t only is detrimental to health but also has societal costs.

9 curring tremendous emotional, financial, and societal costs.

10 llion in treatment costs and $243 million in societal costs.

11 e of older adults and has large economic and societal costs.

12 lone or standard care and modestly increases societal costs.

13 Including societal costs, a longer follow-up period and preparatio

14 of breast cancer to evaluate the incremental societal costs and benefits of status quo versus targete

15 ating condition producing great personal and societal costs and for which there is no effective treat

16 iveness ratio, net present value of lifetime societal costs, and 10-year nominal government expenditu

17 are associated with considerable morbidity, societal costs, and reduced quality of life.

18 Societal costs are enormous.

19 The burden is significantly higher when societal costs are included.

20 n would be higher with the inclusion of such societal costs as lost productivity.

21 nts and providers may not fully consider the societal cost associated with inappropriate antimicrobia

22 ature was reviewed to assess the patient and societal costs associated with age-related macular degen

23 enditures, resulting in no net difference in societal costs associated with managed care.

24 The societal costs associated with vitreoretinal and other o

25 iduals with psychopathy generate substantial societal costs both as a direct financial consequence of

26 nd more effective) since it reduced lifetime societal costs by euro592 per patient and increased QALY

27 nt with lactulose could substantially reduce societal costs by preventing MVAs.

28 07 (95% CI, -$6302 to $2809) in net lifetime societal costs, costs $1312 (95% CI, $222-$2848) per pat

29 Societal cost-effectiveness of a brief prevention progra

30 Societal cost-effectiveness of practice-initiated QI eff

31 Monte Carlo decision model to evaluate the (societal) cost-effectiveness of hepatic metastasectomy i

32 ransition decision model for evaluating the (societal) cost-effectiveness of RF ablation and hepatic

33 The net mean societal cost for bilateral ranibizumab therapy was -$30

34 The distribution of societal costs for adults with mental illnesses enrolled

35 it were possible to completely estimate the societal costs for all acute foodborne diseases and thei

36 Healthcare and societal costs (healthcare plus lost production and unpa

37 e quotient (IQ) score has broad economic and societal cost implications because intelligence affects

38 d disability will help to place the issue of societal costs in a better perspective.

39 Consequently, the use of societal costs in cost-utility analysis typically result

40 Societal costs included transportation and loss of produ

41 Total societal costs, including the cost of IPCC, were lower f

42 Understanding the distribution of societal costs is essential in evaluating health care fi

43 cted to represent significant individual and societal costs: mental health, physical health, harm tow

44 However, vaccination resulted in a net societal cost of $11.17 per person compared with no vacc

45 ost $15,994 per patient, with an incremental societal cost of $1365 per patient and incremental cost-

46 .S. population, our model projects an annual societal cost of $7.1 billion owing to productivity loss

47 The societal cost of a single MVA was estimated at $42,100.

48 the global prevalence of ID and the enormous societal cost of developmental disabilities across the l

49 siderable scope to reduce the individual and societal cost of the illness.

50 The societal cost of these disorders is enormous.

51 role impairment is a major component of the societal costs of epilepsy per se rather than merely due

52 tive affect and behavior, and the associated societal costs of implementing evidence-based education

53 Because of the rising societal costs of osteoporosis anticipated in coming yea

54 Outcome measures included health care and societal costs of rotavirus and benefits and incremental

55 Despite the enormous societal costs of this incapacitating disorder, it is la

56 Societal cost per DALY averted was $10, and the cost per

57 normal (non-trial) conditions the total net societal cost per malaria episode averted in using long-

58 The mean annual societal cost per patient (excluding health system costs

59 Societal cost per unit of improvement on the Children's

60 ate the primary economic outcome of lifetime societal costs per quality-adjusted life-years (QALYs) g

61 e direct medical cost perspective versus the societal cost perspective associated with a vitreoretina

62 for unilateral cataract surgery, whereas the societal cost perspective average cost-utility ratio was

63 The societal cost perspective for bilateral therapy was -$30

64 sociated with a healthcare intervention, the societal cost perspective generally yields a greater fin

65 The societal cost perspective includes direct medical costs;

66 A societal cost perspective is more likely than the third-

67 The 13-year societal cost perspective, financial return on investmen

68 The total Medicare-based societal cost reduction was $783 million.

69 The high societal cost reflects the time that patients are willin

70 ssing self-control might reduce a panoply of societal costs, save taxpayers money, and promote prospe

71 ect costs of care for families, and indirect societal costs should be considered in such decisions.

72 Government must focus on the distribution of societal costs since risk-based financing strategies may

73 l, patient, quality-of-life preferences, and societal costs, to allow the highest quality, most cost-

74 The inclusion of societal costs, versus direct medical costs alone, demon

75 physician visits, or lost workdays; the net societal cost was $65.59 per person compared with no vac

76 During follow-up, return-to-work and other societal costs were documented up to 1 year.

77 Mean societal costs were likewise lower in the high-dose vers

78 Overall societal costs were lower in the ERP group (mean differe

79 Differences in societal costs were somewhat smaller and were not signif